Growth Metrics

Protalix BioTherapeutics (PLX) Amortization of Deferred Charges (2013 - 2023)

Protalix BioTherapeutics' quarterly Amortization of Deferred Charges came in at $59000.0 in Q4 2023, down 22.37% year-on-year from $76000.0 in Q4 2022, and down 1.67% quarter-over-quarter from $60000.0 in Q3 2023.

Protalix BioTherapeutics has reported Amortization of Deferred Charges for 11 years, with the latest figure at $59000.0 in Q4 2023.

  • For the quarter ending Q4 2023, Amortization of Deferred Charges fell 22.37% year-over-year to $59000.0; the trailing twelve-month figure through Dec 2023 stood at $267000.0 (down 11.0% YoY), and the FY2023 full-year result was $267000.0, down 11.0% from the prior year.
  • Amortization of Deferred Charges for Q4 2023 stood at $59000.0, down from $60000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $983000.0 in Q2 2021, with the low at $59000.0 in Q4 2023.
  • Average Amortization of Deferred Charges over 5 years is $485050.0, with a median of $672500.0 recorded in 2019.
  • Year-over-year, Amortization of Deferred Charges gained 16.48% in 2020 and slumped 92.78% in 2022.
  • Tracing PLX's Amortization of Deferred Charges over 5 years: stood at $794000.0 in 2019, then grew by 16.12% to $922000.0 in 2020, then slumped by 88.72% to $104000.0 in 2021, then fell by 26.92% to $76000.0 in 2022, then slipped by 22.37% to $59000.0 in 2023.
  • The last three Amortization of Deferred Charges figures came in at $59000.0 (Q4 2023), $60000.0 (Q3 2023), and $68000.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Protalix BioTherapeutics 164.49 Mn 153.70 Mn 29.62 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 59,000.00
Dec 31, 2023 59,000.00
Sep 30, 2023 60,000.00
Sep 30, 2023 60,000.00
Jun 30, 2023 68,000.00
Jun 30, 2023 68,000.00
Mar 31, 2023 80,000.00
Mar 31, 2023 80,000.00
Dec 31, 2022 76,000.00
Dec 31, 2022 76,000.00
Sep 30, 2022 78,000.00
Sep 30, 2022 78,000.00
Jun 30, 2022 71,000.00
Jun 30, 2022 71,000.00
Mar 31, 2022 75,000.00
Mar 31, 2022 75,000.00
Dec 31, 2021 104,000.00
Dec 31, 2021 104,000.00
Sep 30, 2021 641,000.00
Sep 30, 2021 641,000.00
Jun 30, 2021 983,000.00
Jun 30, 2021 983,000.00
Mar 31, 2021 945,000.00
Mar 31, 2021 945,000.00
Dec 31, 2020 922,000.00
Dec 31, 2020 922,000.00
Sep 30, 2020 883,000.00
Sep 30, 2020 883,000.00
Jun 30, 2020 845,000.00
Jun 30, 2020 845,000.00
Mar 31, 2020 820,000.00
Mar 31, 2020 820,000.00
Dec 31, 2019 794,000.00
Dec 31, 2019 794,000.00
Sep 30, 2019 762,000.00
Sep 30, 2019 762,000.00
Jun 30, 2019 731,000.00
Jun 30, 2019 731,000.00
Mar 31, 2019 704,000.00
Mar 31, 2019 704,000.00
Dec 31, 2018 686,000.00
Dec 31, 2018 686,000.00
Sep 30, 2018 659,000.00
Sep 30, 2018 659,000.00
Jun 30, 2018 638,000.00
Jun 30, 2018 638,000.00
Mar 31, 2018 619,000.00
Mar 31, 2018 619,000.00
Dec 31, 2017 624,000.00
Dec 31, 2017 624,000.00
Sep 30, 2017 569,000.00
Sep 30, 2017 569,000.00
Jun 30, 2017 551,000.00
Jun 30, 2017 551,000.00
Mar 31, 2017 590,000.00
Mar 31, 2017 590,000.00
Dec 31, 2016 235,000.00
Dec 31, 2016 235,000.00
Sep 30, 2016 112,000.00
Sep 30, 2016 112,000.00
Jun 30, 2016 111,000.00
Jun 30, 2016 111,000.00
Mar 31, 2016 110,000.00
Mar 31, 2016 110,000.00
Dec 31, 2015 112,000.00
Dec 31, 2015 112,000.00
Sep 30, 2015 112,000.00
Sep 30, 2015 112,000.00
Jun 30, 2015 111,000.00
Jun 30, 2015 111,000.00
Mar 31, 2015 110,000.00
Mar 31, 2015 110,000.00
Mar 31, 2014 109,000.00
Mar 31, 2014 109,000.00
Dec 31, 2013 112,000.00
Dec 31, 2013 112,000.00